Brooks Laboratories Ltd

Brooks Laboratories Management Change

Brooks Laboratories Ltd announced the resignation of Ms. Krutika Rane, Company Secretary and Compliance Officer, effective October 9, 2026.

Brooks Laboratories Annual General Meeting

Brooks Laboratories Limited conducted its 24th Annual General Meeting on September 3, 2026. Shareholders transacted ordinary business, including the adoption of financial statements and director appointments.

Brooks Laboratories Annual General Meeting

Brooks Laboratories issued an addendum to its 24th Annual General Meeting notice. The amendment modifies Resolution No. 4 regarding corporate guarantee arrangements.

Brooks Laboratories Q1 FY27 Results: Net Loss of ₹1.8 Cr

Brooks Laboratories Ltd reported revenue from operations of ₹23 Cr (-9.8% YoY) and a net loss of ₹1.8 Cr for Q1 FY27.

Key figure

Net loss ₹1.8 Cr

Brooks Laboratories Other Announcement

Brooks Laboratories is informing shareholders about the availability of the Annual Report for FY 2025-26 and requesting KYC updates in compliance with regulatory requirements.

Brooks Laboratories Annual General Meeting

Brooks Laboratories Ltd has issued the notice for its 24th Annual General Meeting scheduled for September 3, 2026, along with the Annual Report for 2025-26.

Brooks Laboratories Board Meeting Date

Brooks Laboratories Limited announced a Board of Directors meeting on 13th August 2026 to approve the unaudited standalone and consolidated financial results.

Brooks Laboratories Management Change

Brooks Laboratories appointed Rajesh Mahajan as President - Trading effective July 17, 2026. He brings over 20 years of experience in pharmaceutical formulations and manufacturing operations.

Brooks Laboratories Merger & Restructuring Worth ₹106.3 Cr

Brooks Laboratories signed a binding MoU to sell a portion of its Brooks Steriscience stake. The deal provides Rs.106.33 Crore cash inflow and retains 32.67% equity.

Value

₹106.3 Cr

Execution

2 years

Brooks Laboratories Other Announcement

Brooks Laboratories Limited filed its shareholding pattern as per Regulation 31(1)(b). The filing details holdings across promoters, institutions, and public shareholders.

Brooks Laboratories Merger & Restructuring

Brooks Laboratories Ltd incorporated a wholly owned subsidiary, Abridge Speciality Limited. This strategic move aims to expand its pharmaceutical business operations.

Brooks Laboratories Other Announcement

Brooks Laboratories filed its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report confirms overall regulatory compliance with no new material deviations.

Brooks Laboratories Management Change

Brooks Laboratories appointed Mr. Prashant Rathi as CEO, effective June 1, 2026. Rathi previously served as CFO and brings 13 years of accounting experience.

Brooks Laboratories Q4 FY26 Results: Turns Profitable, Net Profit ₹1.5 Cr

Brooks Laboratories Ltd reported revenue from operations of ₹20.2 Cr (-13.3% YoY) and net profit of ₹1.5 Cr for Q4 FY26.

Key figure

Net profit ₹1.5 Cr

Brooks Laboratories Financial Results

Brooks Laboratories reported a consolidated total income of ₹86.91 Crore for FY26. The board also appointed Mr. Prashant Rathi as CEO in addition to his CFO role.

Value

₹86.91 Cr

Brooks Laboratories Board Meeting Date

Brooks Laboratories scheduled a board meeting on May 29, 2026, to approve audited FY2026 results. The trading window remains closed until 48 hours post-declaration.

Brooks Laboratories Adverse Business Impact

Brooks Laboratories announced its associate entity decided to terminate the proposed composite scheme of arrangement. The transaction will not be pursued in its current form.

Brooks Laboratories Debt & Borrowing: ₹1.19 Cr

Brooks Laboratories Limited confirmed it does not qualify as a 'Large Corporate' for FY 2025-26 under SEBI debt-raising norms. The company reported outstanding borrowings of ₹1.19 Crore as of March 31, 2026. Its credit rating remains CARE BB; Stable / CARE A4 from CARE Ratings Limited.

Value

₹1.19 Cr

Brooks Laboratories Other Announcement

Atul Ranchal, promoter of Brooks Laboratories Ltd, submitted a declaration under SEBI Takeover Regulations for FY 2025-26. The filing confirms that the promoter and promoter group made no new share encumbrances during the year, other than those already disclosed. This is a routine annual regulatory compliance disclosure.

Execution

Financial Year 2025-26